Feb. 11, 2016—Leica Biosystems and Advanced Cell Diagnostics announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridization assays on Leica Biosystems’ Bond clinical advanced staining instruments. The agreement supports Leica Biosystems’ development and commercialization of fully automated RNAscope-based companion diagnostic tests in partnership with biopharmaceutical companies.
The combination of ACD’s RNAscope technology with Leica Biosystems’ fully automated pathology solutions allows companies and laboratories in clinical markets to integrate the power of new RNA-based biomarker tests into the existing pathology workflow. These tests will be cobranded and commercialized exclusively by Leica Biosystems for use in clinical laboratories around the world.
The RNAscope LS probes and reagents, running on the research use only Bond Rx instrument will also be upgraded to ready-to-use kits with streamlined software. The RNAscope LS products will continue to be branded and commercialized exclusively by ACD. The availability of RNAscope technology on research and clinical advanced staining platforms provides a path for diagnostic test developers to translate their research to the clinic.